Ann: Manufacturing Update - Clinical Trial Remains on Hold, page-51

Just have to let the negative sentiment fade over the next couple of weeks, then the new CEO will be able to relay information relative to the modifications required and the timeframe in which these can be achieved.

Bio technology and drug development for disease remedies is largely target oriented, and once the parameters of the challenge are set out, the optimism returns. With 4-5 million cash and seemingly potentially simple modifications to be made to the antibody structure to satisfy requirements, the optimism could return quite quickly .

We just need these adjustments and timeframe to be set out once the dust settle.
On the basis of risk reward, this is highly desirable and a good time to accumulate. IMO